文献速递乳腺癌

为识别pN2-3状态作为辅助CDK4/6抑制剂治疗指征而行的腋窝淋巴结清扫:随机3期SENOMAC试验的事后分析

Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
PubMed 文献 · Lancet Oncol · 2024-08-06

该事后分析基于SENOMAC试验中符合monarchE队列1特征的1705例管腔型乳腺癌患者,评估腋窝淋巴结清扫(cALND)用于识别pN2-3以指导辅助abemaciclib治疗的获益与危害。中位随访45.2个月,cALND组13%报告严重或极严重手臂功能损害,仅前哨淋巴结活检组为4%;为避免1例5年无侵袭性疾病生存事件需行cALND 104例,并导致9例严重手臂功能损害。作者认为cALND用于该目的应被劝阻。

要点

  • cALND组严重或极严重手臂功能损害13%,仅前哨淋巴结活检组4%(p<0.0001)。
  • 为避免1例5年IDFS事件需行cALND 104例,并导致9例严重手臂功能损害。
  • 作者认为cALND用于识别abemaciclib指征应被劝阻。

核心结论

  • 作为识别abemaciclib指征并进而避免5年IDFS事件的方法,cALND带来严重或极严重手臂并发症的显著风险,作者认为应劝阻cALND用于该目的。

研究设计与样本

  • SENOMAC为随机3期试验,2015年1月31日至2021年12月31日入组2766例,随机分至cALND(n=1384)或仅前哨淋巴结活检(n=1382),符合方案人群2540例。
  • 本事后分析纳入1705例符合monarchE队列1特征的管腔型ER阳性、HER2阴性、T1-2、组织学1-2级、肿瘤≤5 cm患者,其中802例(47%)行cALND,903例(53%)仅行前哨淋巴结活检。
  • 主要目标为确定cALND术后1年患者报告严重或极严重手臂功能损害(Lymph-ICF问卷)的人数,以避免1例5年IDFS事件(使用monarchE队列1的IDFS事件数据,辅助abemaciclib 2年)。
  • SENOMAC试验注册号NCT02240472,已停止入组但仍在进行。

主要发现

  • 1705例中位随机年龄62岁(IQR 52-71),1699例(>99%)为女性,6例(<1%)为男性。
  • 1342例问卷应答者中位随访45.2个月(IQR 25.6-59.8;数据截止2023年11月17日)。
  • cALND组634例中84例(13%)报告严重或极严重手臂功能损害,仅前哨淋巴结活检组708例中30例(4%)报告(χ2检验p<0.0001)。
  • 为避免1例5年IDFS事件需行cALND 104例,并导致9例术后1年严重或极严重手臂功能损害。

临床怎么用

  • 作者认为,cALND作为识别abemaciclib指征的方法带来严重或极严重手臂并发症的显著风险,应劝阻cALND用于该目的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In luminal breast cancer, adjuvant CDK4/6 inhibitors (eg, abemaciclib) improve invasive disease-free survival. In patients with T1-2, grade 1-2 tumours, and one or two sentinel lymph node metastases, completion axillary lymph node dissection (cALND) is the only prognostic tool available that can reveal four or more nodal metastases (pN2-3), which is the only indication for adjuvant abemaciclib in this setting. However, this technique can lead to substantial arm morbidity in patients. We aimed to pragmatically describe the potential benefit and harm of this strategy on the individual patient level in patients from the ongoing SENOMAC trial. METHODS: In the randomised, phase 3, SENOMAC trial, patients aged 18 years or older, of any performance status, with clinically node-negative T1-T3 breast cancer and one or two sentinel node macrometastases from 67 sites in five European countries (Denmark, Germany, Greece, Italy, and Sweden) were randomly assigned (1:1), via permutated block randomisation (random block size of 2 and 4) stratified by country, to either cALND or its omission (ie, they had a sentinel lymph node biopsy only). The primary outcome is overall survival, which is yet to be reported. In this post-hoc analysis, patients from the SENOMAC per-protocol population, with luminal oestrogen-receptor positive, HER2-negative, T1-2, histological grade 1-2 breast cancer, with tumour size of 5 cm or smaller were selected to match the characteristics of cohort 1 of the monarchE trial who would only have an indication for adjuvant abemaciclib if found to have 4 or more nodal metastases. The primary study objective was to determine the number of patients who developed patient-reported severe or very severe impairment of physical arm function after cALND (as measured by the Lymphedema Functioning, Disability, and Health [Lymph-ICF] Questionnaire) 1 year after surgery to avoid one invasive disease-free survival event at 5 years with 2 years of adjuvant abemaciclib, using invasive disease-free survival event data from cohort 1 of the monarchE trial. The SENOMAC trial is registered with ClincialTrials.gov, NCT02240472, and is closed to accrual and ongoing. FINDINGS: Between Jan 31, 2015, and Dec 31, 2021, 2766 patients were enrolled in SENOMAC and randomly assigned to cALND (n=1384) or sentinel node biopsy only (n=1382), of whom 2540 were included in the per-protocol population. 1705 (67%) of 2540 patients met this post-hoc study's eligibility criteria, of whom 802 (47%) had a cALND and 903 (53%) had a sentinel lymph node biopsy only. Median age at randomisation was 62 years (IQR 52-71), 1699 (>99%) of 1705 patients were female, and six (<1%) were male. Among 1342 patients who responded to questionnaires, after a median follow-up of 45·2 months (IQR 25·6-59·8; data cutoff Nov 17, 2023), patient-reported severe or very severe impairment of physical arm function was reported in 84 (13%) of 634 patients who had cALND versus 30 (4%) of 708 who had sentinel lymph node biopsy only (χ2 test p<0·0001). To avoid one invasive disease-free survival event at 5 years with adjuvant abemaciclib, cALND would need to be performed in 104 patients, and would result in nine patients having severe or very severe impairment of physical arm function 1 year after surgery. INTERPRETATION: As a method to potentially identify an indication for abemaciclib, and subsequently avoid invasive disease-free survival events at 5 years with 2 years of adjuvant abemaciclib, cALND carries a substantial risk of severe or very severe arm morbidity and so cALND should be discouraged for this purpose. FUNDING: Swedish Research Council, the Swedish Cancer Society, the Nordic Cancer Union, and the Swedish Breast Cancer Association.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. de Boniface J, Appelgren M, Szulkin R, et al. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. Lancet Oncol. 2024. PMID: 39121881. doi:10.1016/S1470-2045(24)00350-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。